Message from the Guest Editor

Dear Colleagues,

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Therapeutic approach varies according to tumor location (colonic or rectal) and pTNM stage, the latter representing a main prognostic factor. In view of the overall good prognosis of nonmetastatic CRC, adjuvant treatments are not recommended in pTNM stage I, and their use is controversial in pTNM stage II. However, 10%–20% of patients undergo disease progression and would have benefitted from adjuvant therapies.

The identification of patients with nonmetastatic CRC at a high risk of progression is a future research challenge. In this regard, studies using liquid biopsy or searching for histological and molecular factors associated with metastatization could provide relevant information. In recent years, immune check point inhibitors have shown promising results in the treatment of a subset of metastatic CRC with high microsatellite instability (MSI).

The aim of this Special Issue is to give an insight into the process of metastatization in CRC and into molecular and histopathological factors which may be predictive of novel therapies for this tumor.

Prof. Valeria Barresi
Guest Editor

dippi.com/si/40295